Edge Therapeutics appoints chief operating officer
Mr. Brennan joins Edge with about 20 years of senior-level management, commercial and business development experience in the biopharmaceutical industry.
Most recently, Mr. Brennan served as Chief Operating Officer and Executive Vice President of Insys Therapeutics, Inc. since November 2015, where he was responsible for all commercial and general operating activities, including rebuilding Insys’ commercial leadership team and practices.
Previously, Mr. Brennan held multiple leadership positions at Lundbeck, Inc., including serving as Vice President and Group General Manager of the Neurology Business Unit and U.S. Business Development Group, where he led the launch of four specialty orphan products.
Prior to Lundbeck, Mr. Brennan served at Abbott Laboratories, where he led sales and product launch preparation for the company’s acute care hospital product pharmaceutical group.
He also brings sales, marketing and new product development expertise from his decade of service at Eli Lilly and Company.
Mr. Brennan received a B.A. from the University of Notre Dame and an M.B.A. degree, with distinction, from the Kellogg Graduate School of Business at Northwestern University. ■
LATEST MOVES FROM New Jersey
- Wireless Telecom Group appoints Daniel Monopoli as CTO
- New Jersey Resources names Maureen Borkowski to board
- Milestone Scientific appoints Daniel Goldberger as CEO
- Celldex changes management team
- Pacira Pharmaceuticals appoints Mark I. Froimson to board
More inside POST
John Holland lands $1bn+ Sydney scheme Companies